Objective: The appearance of atrial fibrillation is associated with significant clinical deterioration in patients with obstructive hypertrophic cardiomyopathy; therefore, maintenance of sinus rhythm is desirable. Guidelines and most articles have reported the results of catheter ablation and pharmacologic atrial fibrillation treatment; nevertheless, data regarding concomitant procedures during septal myectomy are limited. The aim of this study was to assess the outcomes of concomitant atrial fibrillation treatment in patients with obstructive hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is a genetic disease with increasing left ventricle wall thickness, morphologic abnormalities of mitral valve apparatus, and progressive heart failure. 1, 2 Left ventricular outflow tract (LVOT) obstruction, systolic anterior motion, and mitral regurgitation (MR) lead to high left atrial pressure and dilatation, increasing the risk of atrial fibrillation (AF). [3] [4] [5] The prevalence of AF in patients with HCM is approximately 18% to 25%. 4, 6 The appearance of AF increases long-term mortality and the incidence of thromboembolic events, and significantly reduces quality of life. 5, 7 AF with irregular tachysystolic rhythm in patients with HCM leads to loss of atrial contraction and reduced filling time to intensify left ventricle diastolic dysfunction in those with HCM. Pharmacologic therapy and radiofrequency catheter ablation are widely used for the maintenance of sinus rhythm in such patients. 2, [7] [8] [9] Antiarrhythmic drug therapy has minimal evidence and low efficiency for sinus rhythm restoration. 8 Radiofrequency catheter ablation has been proven effective for AF treatment in patients with HCM; however, the rate of AF recurrence is high, ranging from 48% to 72% after a single ablation procedure. 2, [7] [8] [9] Data regarding concomitant surgical AF treatment during septal myectomy in patients with obstructive HCM are limited. 10 Our objective was to assess the effectiveness and safety of concomitant Maze IV procedure during septal myectomy in patients with obstructive HCM.
MATERIALS AND METHODS Patient Characteristics
Patient recruitment for the study was prospective with continuous observation. End points were freedom from AF recurrence, LVOT gradients, New York Heart Association class, and quality of life assessed with the Short Form-36 questionnaire. The local Ethical Committee approved this study, and all patients provided written informed consent. The present study was conducted in compliance with the Declaration of Helsinki.
Between January 2010 and May 2013, 187 patients underwent extended myectomy procedures. In 45 patients (24.1%), concomitant AF ablation was performed (Consort diagram shown in Figure E1 ). Mean age of patients was 52.8 AE 14.2 years (range, 22-74 years) ( Table 1) . Obstructive HCM was the primary indication for surgery according 2011 American College of Cardiology Foundation/American Heart Association guidelines.
Surgical Technique
In all procedures, exposure was achieved through a midline sternotomy with standard cardiopulmonary bypass, bicaval cannulation, and mild hypothermia (33 C-34 C). For myocardial protection, cold cardioplegic crystalloid solution was used (Custodiol Dr Kohler Pharma, Alsbach-Hahnlein, Germany) with antegrade root flow. Transaortic extended myectomy was performed in all cases using the operative technique previously described by Morrow 11 and modified by Messmer 12 (Figure 1, A) . Cox-Maze IV procedure included ablation lines created by using an Isolator Synergy bipolar device (AtriCure, Inc, Cincinnati, Ohio) with applications 8 to 10 times at each line ( Figure 2, A and B) , and cryolesions created by applying cryoICE cryoablation probes (AtriCure, Inc) to the mitral and tricuspid annulus (Figure 1, B) . The left atrial appendage was excluded using an external double-layer 4/0 polypropylene suture in all cases. Mitral valve intervention (repair or replacement) was performed in all cases.
Exit and entrance block of the pulmonary veins (electrophysiologic disconnection of the pulmonary veins from the left atrium during pacing) and for the posterior left atrium wall (''box lesion'') were assessed immediately before bypass weaning in all patients using monopolar stimulation probe.
To assess residual MR, systolic anterior motion syndrome, and LVOT obstruction after the procedure, intraoperative transesophageal echocardiography was used. Rapid dual-chamber or atrial pacing (in cases of adequate atrial valve conductance) with 80 to 86 beats/minute was established in all patients. For further information, see the intraoperative Video 1 with subtitles available online.
Drug Management
Maintenance antiarrhythmic therapy consisted of amiodarone 600 to 1200 mg before the operation and 200 mg per day for 3 months postoperatively. Antiarrhythmic medication was discontinued at the end of the blanking period (3 months) after rhythm monitoring. During the followup period in patients with AF recurrences, we restarted amiodarone in paroxysmal patients. The decision to stop anticoagulation therapy with Coumadin in patients without mechanical prostheses was based on echocardiography (completeness of left atrial appendage closure, presence of atrial contractility) and Holter data after 6 months. Patients with a mechanical mitral valve were kept on lifelong anticoagulation therapy. Nonvasodilatating b-blockers were prescribed for all patients after surgery.
Cardiac Rhythm Assessment
Patient follow-up examinations were scheduled every 6 months postoperatively at our outpatient department or the referring cardiologist's office. The primary end point of this study was freedom from atrial arrhythmia recurrence, defined as any documented AF, atrial flutter, or atrial tachycardia episode lasting more 30 seconds after a 3-month blanking period. Cardiac rhythm was monitored with 72-hour Holter monitoring in all patients. 
Statistical Analysis

RESULTS
Mitral valve repair and replacement were performed in 19 patients (42.2%) and 5 patients (11.1%), respectively. Mitral valve repair included papillary muscle mobilization in 19 patients (100%), secondary chord (from 2 to 6) resection in 19 patients (100%), longitudinal papillary muscle resection (in cases with papillary muscles exceeding 15 mm) in 12 patients (63.1%), and excision of abnormal papillary muscles in 1 patient (5.3%). Mean crossclamp and ablation times were 61.7 AE 26.2 minutes and 28.8 AE 7.2 minutes, respectively.
Intraoperative testing in all 6 patients who underwent previous catheter AF ablation did not confirm pulmonary vein isolation from the previous procedure. Sensing and pacing maneuvers verified isolation of pulmonary veins and posterior box in all patients without requirement of any repeated ablation. A consolidated conduction block was successfully achieved in all patients after the procedure. There were no early deaths. Peak LVOT gradient after the procedure according to transesophageal echocardiography and direct measurement was 12.6 AE 5.5 mm Hg and 10.2 AE 4.4 mm Hg, respectively ( Table 2) . One patient was reexplored for bleeding. We did not observe any specific AF ablation-related complications or postoperative cerebral ischemic events. Thirty-one patients (68.9%) had a transit sinus node dysfunction with complete recovery at 4 to 10 days after surgery. Early AF paroxysm recurrence was observed in 2 patients (4.4%) and pharmacologically cardioverted with amiodarone. We did not have any patients with a preexisting dual-chamber pacemaker. Complete atrial valve block was the main complication of extended myectomy, which necessitated pacemaker implantation in 2 patients (4.4%). We interrogated pacemakers in those 2 patients and did not reveal any AF paroxysms. Left bundle branch block was detected in 34 patients (75.5%).
Hospital length of stay was 12.4 AE 2.4 days. Stable sinus rhythm was documented in 43 patients at discharge, and 2 patients had pacemaker rhythm with P-wave pacing.
The mean follow-up period was 23.7 AE 1.3 months. Holter ECG was performed in all patients at 12 months and in 87% (n ¼ 39) at 24 months. One sudden cardiac death (2.2%) occurred 12 months postmyectomy. One noncardiac death (malignancy) occurred 4 years after surgery. Patients who died underwent a pathoanatomic examination, and autopsy protocol was obtained.
The repeated-measures analysis of variance revealed significant changes in echocardiographic results ( Table 2) . At 24-month follow-up, the left ventricular end-diastolic volume was increased, the LVOT gradient was decreased to 11.3 AE 6.4 mm Hg, and basal septal thickness was decreased to 15.2 AE 2.8 mm compared with values before surgery (P <.01). There are no significant (grade !2) MR recurrences. At the 2-year follow-up, 86.5% AE 5.1% of patients (95% confidence interval [CI], 72.4-93.7) were free from AF recurrence and any antiarrhythmic drugs. Cardiac rhythm statuses during sequential 3-month, 6-month, 12month, 18-month, and 24-month points after surgery are shown in Table E1 and illustrated in Figure 3 . Rates of AF freedom at each time point were 100% (45 patients) at 6 months, 93.3% (42 patients) at 1 year, and 82.2% (37 patients) at 24 months. Post hoc pairwise comparison revealed that differences in freedom from atrial tachyarrhythmias at 24 months versus discharge/3/6 months were significant. There was no significant different in freedom from AF/atrial flutter/atrial tachycardia between the paroxysmal and persistent subsets through 24 months (Figure 4 ).
Six patients with AF recurrences at follow-up had paroxysmal rhythm disturbances, and they were primarily in sinus rhythm according to 72-hour Holter. Among them, 4 patients had recovered sinus rhythm, and 2 patients had observed AF paroxysm at the next examination. Only 2 patients had long-standing persistent AF. We decided to use rate control instead of rhythm control drug management for these 2 patients. Five patients with a mechanical mitral valve were kept on lifelong anticoagulation therapy. 
DISCUSSION
This study presents the results of concomitant AF ablation in patients with obstructive HCM. The Cox-Maze III procedure in patients with cardiac disease and AF who underwent concomitant interventions was previously reported to achieve a success rate of more than 95% sinus rhythm restoration at 10 years. 13 Modification of the Cox-Maze III procedure by eliminating the traditional ''cut and sew'' approach has been proposed as the Maze IV technique. The main aim of this procedure was to simplify and shorten the operation without reducing short-term efficacy, as was supported by a prospective, single-center clinical trial. 13 Despite the excellent results of the Maze IV procedure for concomitant AF treatment, data from patients with obstructive HCM scheduled for myectomy are limited.
The first report of the concomitant Maze procedure during extended myectomy was published in 2004 by Chen and colleagues 10 from the Cleveland Clinic, who reported only a 60% freedom from AF recurrence after 15 months based on a limited series of 10 patients. Bassiouny and colleagues 14 published the largest retrospective analysis of nonpharmacologic AF treatment in patients with HCM. They obtained more optimistic results after concomitant ablation, with 74% and 68% AF freedom for 1 and 2 years, respectively. However, the surgical techniques used in that study were varied, including complete ''cut and sew'' Maze III, modified procedures using cryothermia or radiofrequency energy, and lone pulmonary vein isolation by applying a bipolar clamp.
In the present study, we achieved an 82.2% rate of sinus rhythm preservation at 24-month follow-up, which is substantially higher than in other studies. The low success rate of concomitant AF ablation is associated with hypertrophy of atrial myocytes, 15 which is common in HCM and does not allow achieving the complete transmural lesion during the procedure. This fact is confirmed by the observation of pulmonary vein conduction recovery on repeat catheter ablation in most patients who had undergone modified Maze or limited pulmonary vein isolation with cryotherapy/ radiofrequency energy but not in patients who underwent the ''cut and sew'' procedure. 14 Reconnection is not rare even in patients with mitral valve disease along with dilatation and thinning of the atrial wall 16 and can be a more significant problem in cases of severe atrial hypertrophy leading to failure of the ablation procedure. In our study, we also revealed failure of previous catheter pulmonary vein isolation in all cases. We believe that the high success rate in our series is based on features of the ablation procedures. In all cases, we performed the complete Maze IV procedure with bipolar clamps and cryolesions for mitral and tricuspid lines instead of more limited schemes, such as left atrial mini-Maze or isolation pulmonary veins alone. We performed multiple applications (up to 10) with the bipolar clamp because the atrial wall thickness exceeded 5 mm and could be a cause of incomplete transmural lesion postoperatively.
Predictors associated with a lower likelihood of success after concomitant AF ablation are well known. Cox regression analysis in the study by Bassiouny and colleagues 14 confirmed them for patients with HCM: AF duration (OR, 0.66; 95% CI, 0.49-0.90; R ¼ .008) and AF type (persistent and long-standing persistent) (OR, 0.38; 95% CI, 0.17-0.88; R ¼ .024). 14 In our study, older age was associated with a greater risk for AF recurrence during follow-up.
Sinus node dysfunction requiring permanent pacemaker implantation is another negative outcome of the concomitant Maze procedure, occurring in 6% to 13% of cases within 30 days after the procedure and 6% to 10% of cases at 1-year follow-up. 17 Robertson and colleagues 17 reported that only age was an independent predictor for permanent pacemaker insertion (OR, 1.10; 95% CI, 1.06-1.14; P<.001). In another study, demographic data did not affect the pacemaker implantation rate; however, biatrial procedures were associated with significantly increased rates of sinus node dysfunction compared with isolated left-sided ablation (6.3% vs 13.6%; P ¼ .028). 18 In the present study, we performed a biatrial Maze procedure in all cases but did not observe any incidents of permanent sinus node dysfunction. This result could be explained by young age of patients in this cohort (52.8 AE 14.2 years) and possibly nonrheumatic AF reason without long duration (17.3 AE 8.5 months).
At the 2-year follow-up, we observed improvement of functional status, absence of LVOT obstruction recurrence, and MR 2þ or greater. We also found improvement in the quality of life 1 year after surgery, which is consistent with other reports. 10, 12, 14 In our HCM subset, freedom from recurrent atrial tachyarrhythmias after concomitant Cox-Maze IV procedure at 2 years was 82%, which looks similar to the rheumatic and degenerative cohort (90% and 80%, respectively) at the same time point. 19 
Study Limitations
This study included a limited number of patients without a control group; moreover, 72-hour Holter monitoring instead of continuous loop recording was used. We did not precisely examine an atrial transport function, which might affect the results, especially in those with paroxysmal AF. The study results can be considered for patients with HCM with a 2-year follow-up period. Longer-term follow-up results are needed.
CONCLUSIONS
Concomitant Maze IV procedure during septal myectomy in patients with obstructive HCM was able to safely and effectively eliminate AF, improving functional capacity and quality of life. Concomitant surgical AF ablation may be considered for patients with HCM with AF who are scheduled for myectomy. 
